William Xiang is the Managing Director of Nucleate Taiwan and Vice President of Talent Management for Nucleate Headquarters, USA. He is responsible for building the non-profit’s presence in Taiwan with his co-founder Jack Liang, a founding Partner at an early-stage venture capital fund. For Headquarters, he is responsible for creating strategy and processes with the executive leadership team on developing Nucleate’s global talent funnel. He is also Head of Strategy and R&D Operations at XWPharma, a venture-backed neuroscience biotech company focused on novel drug development.
He holds a variety of responsibilities for the company including fundraising, business development, portfolio strategy and management, and operations. He has helped the company raise $75 million, led the development of one clinical program from animal studies to Phase 3 ready and another clinical program from molecular design to Phase 2 ready. He also led the expansion of XWPharma from China to Taiwan, Australia and the United States while building a team of over 40 full-time employees, expert consultants and Key Opinion Leaders. Prior to XWPharma, Willie held various roles in Corporate Strategy, Investment Management, Data Analytics and Sales for the world’s largest mutual fund investment firm Vanguard.